Treprostinil Sodium Patent Expiration

Treprostinil Sodium was first introduced by Liquidia Technologies Inc in its drug Yutrepia on May 23, 2025.


Treprostinil Sodium Patents

Given below is the list of patents protecting Treprostinil Sodium, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Yutrepia US10898494 Dry powder treprostinil for the treatment of pulmonary hypertension May 05, 2037 Liquidia Tech
Yutrepia US11660304 Dry powder treprostinil for the treatment of pulmonary hypertension May 05, 2037 Liquidia Tech
Yutrepia US11712442 Dry powder treprostinil for the treatment of pulmonary hypertension May 05, 2037 Liquidia Tech
Yutrepia US11744835 Dry powder treprostinil for the treatment of pulmonary hypertension May 05, 2037 Liquidia Tech
Yutrepia US11744836 Dry powder treprostinil for the treatment of pulmonary hypertension May 05, 2037 Liquidia Tech



Treprostinil Sodium's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List